NCOR1 and urinary bladder carcinoma: To explore the association between NCOR1 mutations and the efficacy of ICIs in bladder cancer patients, we used cBioportal to download the ICI-treated bladder cancer cohort (Samstein et al.), including 215 patients receiving ICIs (PD-(L)1 and/or CTLA-4 inhibitors.